|Bid||3.1200 x 900|
|Ask||3.1400 x 1000|
|Day's Range||3.0600 - 3.2700|
|52 Week Range||2.8600 - 37.2400|
|Beta (3Y Monthly)||2.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
CHF Solutions (CHFS), today announced highlights from the sponsored session from the American Association for Thoracic Surgery Annual Meeting moderated by Daniel Beckles, M.D., Ph.D. of United Health Services Hospitals in Binghamton, N.Y. The full session can be found on the company’s website at www.chf-solutions.com.
CHF Solutions, Inc. (CHFS), today announced that, on May 23, 2019, the independent directors approved five equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to five individuals entering into employment with the Company. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with entering into employment with CHF Solutions, the five individuals, who were not previously employees or directors of CHF Solutions, received options to purchase an aggregate of 96,489 shares of the Company’s common stock.
CHF Solutions (CHFS) today announces that Sussex County, Delaware-based health system, Beebe Healthcare, has initiated offering ultrafiltration therapy using the company’s Aquadex FlexFlow system. “This treatment has become a very viable and useful alternative for appropriate heart failure patients, and we are excited to have it available at Beebe Healthcare,” said Alberto Rosa, MD, Medical Director of Heart Failure.
EDEN PRAIRIE, Minn., May 07, 2019 -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the first quarter ended March 31, 2019, which included the following.
CHF Solutions (CHFS) today announces it has hired Nestor Jaramillo, Jr. as its new chief commercial officer, effective May 7, 2019. Prior to joining CHF Solutions, Mr. Jaramillo was president and CEO of Innerspace Neuro Solutions, Inc., a Tustin, Calif.-based commercial-stage medical technology company that developed, manufactured and distributed an intracranial pressure monitoring system. He also worked in a variety of capacities at startup Transoma Medical, St. Jude Medical, and at Medtronic. In addition, he also spent seven years as a managing director of healthcare investment banking at both Cherry Tree & Associates and Craig-Hallum Capital, both in Minneapolis. He holds an engineering degree from the University of North Dakota and a Master of Business Administration from the University of St. Thomas in Minneapolis.
EDEN PRAIRIE, Minn., April 30, 2019 -- CHF Solutions, Inc. (NASDAQ: CHFS) announces today that its first quarter 2019 financial results will be released on Tuesday, May 7,.
EDEN PRAIRIE, Minn., April 23, 2019 -- CHF Solutions (Nasdaq: CHFS), today announced it will be sponsoring a CT Theatre Session at the American Association for Thoracic Surgery.
EDEN PRAIRIE, Minn., April 16, 2019 -- CHF Solutions (Nasdaq: CHFS) today announced that Heart Hospital at Saint Francis has launched an ultrafiltration program using the.
The Oklahoma Heart Institute is located on the campus of Hillcrest Medical Center in Tulsa, Oklahoma and combines the expertise of nationally recognized cardiovascular physicians with the region’s most advanced technology and personalized patient care. Hillcrest Medical Center is a 620-bed hospital located in Tulsa, Oklahoma.
CHF Solutions (CHFS) today announced the submission of a method of use application to the United States Patent and Trademark Administration for pediatric use of its Aquadex Flex Flow System. Illustrative claims in the application include customizable circuit volume for optimizing pediatric patient hemodynamics and a mechanism to ensure the safety of pediatric patients. “We remain dedicated to the innovation of our technology and to optimizing the application of our Aquadex FlexFlow system, a safe, effective and clinically-proven solution to manage fluid overload,” said John Erb, chairman and CEO of CHF Solutions.
CHF Solutions (CHFS), today announced it will be exhibiting at the 2019 Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) on April 3-6, 2019 at the Lowes Meeting Complex in Orlando, Fla. The company can be found on the exhibition floor at booth #408.
CHF Solutions (CHFS), today announced the publication of “Ultrafiltration vs. Diuretics for Treatment of Fluid Overload in Patients with Heart Failure: A Hospital Cost Analysis” in the Journal of Medical Economics showing that the use of ultrafiltration therapy with the company’s Aquadex Flex Flow System in heart failure patients reduces hospital readmissions and durations of stay which lowers hospital costs over a 90-day period, compared to diuretic therapy. The study examined clinical data from the literature and hospital data from the Healthcare Cost and Utilization Project to follow a decision analytic framework outlining treatment decision, probabilistic outcomes and associated costs for treating heart failure patients with fluid overload (hypervolemia) with either ultrafiltration or diuretic therapy. Results showed that while initial healthcare costs associated with ultrafiltration therapy were higher, fluid removal with ultrafiltration, such as with the Aquadex Flex Flow system, reduced hospital readmissions, leading to a cost savings of $3,975, or nearly 15 percent, compared to diuretic therapy. The study abstract can be accessed via https://www.ncbi.nlm.nih.gov/pubmed/30775944.
EDEN PRAIRIE, Minn., March 12, 2019 -- CHF Solutions, Inc. (NASDAQ:CHFS) today announced the closing of an underwritten public offering of units for gross proceeds of $12.42.
CHF Solutions, Inc. (CHFS) today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $10.8 million prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions. The conversion price of the preferred stock issued in the transaction as well as the exercise price of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features.
We have presented five ETFs & stocks that have easily crushed the Russell 2000 index this year and are likely to continue their strong performance.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in CHF Solutions, Inc. (NASDAQ:CHFS) haveRead More...
EDEN PRAIRIE, Minn., Feb. 20, 2019 -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter and year ended December 31, 2018, which included the.
EDEN PRAIRIE, Minn., Feb. 19, 2019 -- CHF Solutions (Nasdaq: CHFS), today announced the initiation of a distribution agreement in the Brazilian market with Bragenix, LTDA..
EDEN PRAIRIE, Minn., Feb. 13, 2019 -- CHF Solutions, Inc. (NASDAQ: CHFS) announces today that its fourth quarter and year-end 2018 financial results will be released on.
CHF Solutions (CHFS), today announced the initiation of a distribution agreement in the Indian market with Wayinia Lifesciences. This agreement expands the company’s sales outreach in Asia, while opening new access to one of the larger population centers in the region. Currently, there are around three million reports of heart failure in India, with an additional one million new incidents being reported annually. Wayinia Lifesciences was established in 2015 with roots from India and Norway.
EDEN PRAIRIE, Minn., Jan. 24, 2019 -- CHF Solutions (Nasdaq: CHFS), today announced it will be sponsoring a breakfast symposium at the Society of Thoracic Surgeons Annual.
CHF Solutions (CHFS) today announced the filing of two new patent applications with the United States Patent and Trademark Office (USPTO) designed to deepen the company’s intellectual property protection for its Aquadex FlexFlow system. One of the two applications is based on the company’s design for a wearable device designed to assist in maintaining peripheral venous blood flow access in the arm during aquapheresis treatment with the Aquadex FlexFlow system. The second application includes multiple potential new features and improvements to the diagnostic capabilities of the Aquadex FlexFlow system, which, if incorporated into the product, would be designed to help ensure optimal patient fluid balance and to dramatically improve usability for healthcare providers.
EDEN PRAIRIE, Minn., Dec. 05, 2018 -- CHF Solutions (Nasdaq: CHFS), today announced that it will be exhibiting at Heart Failure University from December 7-9, 2018 at the Los.
EDEN PRAIRIE, MN / ACCESSWIRE / November 28, 2018 / CHF Solutions (NASDAQ: CHFS), today announced that it will be presenting at the 11th annual LD Micro Main Event on Wednesday, December 5th at 7:30AM ...